¹⁸F-Fluorodeoxyglucose PET-CT evaluation after one course of neoadjuvant therapy fails to predict pCR in HER2 + BC patients: a prospective and multicentric French study.

ABSTRACT:

Background

¹⁸F-FDG PET-CT has emerged as a powerful imaging tool for initial staging and prognosis evaluation of patients with Breast Cancer (BC). However, previous studies are inconsistent on attributing a predictive value to the pathological Complete Response (pCR) determined by PET-CT. Our objective was to assess the association between pCR and ¹⁸F-FDG PET-CT findings in patients with HER2+ BC in neoadjuvant setting.

Methods

We collected data from patients enrolled in the prospective and multicentric French clinical trial NeoTOP (NCT02339532) who underwent ¹⁸F-FDG PET-CT before and after their first course of neoadjuvant treatment (depending on topoisomerase 2-α amplification status: 3 cycles of FEC 100 followed by 3 cycles of Docetaxel +

SUBMITTER: Chanchou M 

PROVIDER: S-EPMC12781833 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature